Introduction
The management of failed arthroplasty and fracture about the proximal femur remains a challenge for the revision arthroplasty surgeon. A multitude of factors can contribute to the eventual loss of proximal femoral bone stock including septic and aseptic osteolysis, peri-prosthetic fracture, failure of internal fixation following proximal femoral fracture, and multiple previous revision procedures (1) (2) (3) (4) (5) (6) (7) (8) . Whilst a multitude of options exist for the management of proximal femoral bone loss, including impaction grafting, allograft prosthesis composite and long cemented or press-fit arthroplasty, many of these techniques necessitate limitations on loss since 2007. We advocate its use for the rapid recovery and immediate mobilisation afforded to patients, particularly those in a poor state of general health, or advancing age. Whilst it is not intended to replace more bone and soft tissue preserving reconstruction options, it may offer improved patient function and relief of pain compared to non-surgical management. Calculating the risk and benefit in this often complex scenario is multifaceted and there is little comparison or outcome report in the literature to aid the decision making process for the clinician and patient.
The aim of this study, therefore, was to retrospectively review our experience of proximal femoral endoprosthetic replacement (EPR) as the salvage treatment for failed arthroplasty or fracture fixation. The outcomes measured included mortality within the first 90 postoperative days; complications; patient-reported outcomes and revision of the implant for any reason.
Patients and methods
The study population comprised a retrospective assessment of all patients undergoing proximal femoral endoprosthetic replacement for a non-oncological diagnosis in a single institution between January 2007 and January 2015, with a minimum 3-month clinical and radiological follow-up. Institutional ethical review board approval was given for the assessment of patient identifiable data and patient reported outcomes. Data recorded included patient demographics, the indication for EPR, and the number and nature of previous operations.
The study population comprised 37 patients, 23 female and 14 male, with a mean age of 80 years (range 49-94 years). The average number of previous hip operations was 2.5 (range 1-9) with a mean duration between the last hip procedure and definitive re-implantation with EPR of 29 months (range 6-102 months).
The indications for EPR were significant compromise of proximal femoral bone stock, where other surgical options such as impaction grafting of long-stemmed biological fixation would require extensive surgery and not guarantee full weight bearing status immediately postoperatively. Specifically in our cohort this indication included failure of fixation following proximal femoral fracture in 15 patients (Fig. 1) , a Vancouver type-B3 periprosthetic fracture (associated with a loose femoral stem and proximal femoral bone loss) (12) in 8 patients, aseptic loosening on the background of multiple previous revisions with significant proximal femoral bone loss in 8 patients (Fig. 2) , following periprosthetic joint infection in 4 patients, and following previous paediatric arthrodesis in 2 patients. In 1 of these patients, there had been an attempt at take-down of the arthrodesis resulting in deficiency of the proximal femur, pelvic discontinuity and an abandoned reimplantation with subsequent excision arthroplasty.
Clinical and radiological follow-up was performed retrospectively on all patients. The mean duration of follow-up was 33 months (range 6-84 months). No patients were lost to follow-up. Patient reported outcomes were measured by the Oxford Hip Score (OHS) (13) and were recorded preoperatively and at last follow-up. For patients with periprosthetic fracture, the score was completed by the patient for the state of the hip prior to fracture. Patient comorbidities were recorded preoperatively and classified according to the Charlson comorbidity index (14) , whilst patient physiological status at the time of EPR was recorded by the American Society of Aneasthesiologists grade. 14 patients had an ASA score of 2 while the remaining patients had an ASA score of 3. The mean age adjusted Charlson comorbidity score was 4 (range [1] [2] [3] [4] [5] [6] [7] [8] .
Implant survival was defined as revision for any cause. All procedures were performed by the senior author via a posterior approach. The mean operative time was 129 minutes (range 69-213 minutes). In all cases a trochanteric slide osteotomy was utilised (15, 16) , maintaining the attachment of both vastus lateralis and the hip abductors (Fig. 2) . In all cases, the trochanteric fragment was reattached to the shoulder of the prosthesis which incorporates a hydroxyapatite coating, using cables. Failure of this reattachment was assessed clinically and radiologically, as proximal migration of the trochanteric fragment or development of a Trendelenburg gait, but was not seen in any of the cases, although integration of the fragment cannot be presumed on this basis. Acetabular reconstruction was assessed on a case-by-case basis and was indicated by the presence of joint space narrowing and acetabular sided subchondral sclerosis on preoperative radiographs. In 13 patients, where there was no clinical or radiological indication, acetabular reconstruction was not undertaken. For these patients a bipolar femoral head (7 patients) or a unipolar head (6 patients) was used. In 6 patients, an uncemented acetabular prosthesis was used and in the remaining 18 patients a cemented dual mobility acetabular prosthesis was used (SERF, Omnilife Science Inc.), in combination with a pedestalled periacetabular prosthesis (Stanmore Implants Worldwide, Elstree, London, UK) in 5 patients. The type of acetabular reconstruction was dictated by the degree of bone loss, and the minimum to provide stable fixation and appropriate orientation was used. Acetabular reconstruction was aimed at reducing the risk of post operative instability seen following proximal femoral replacement, balanced against the increased surgical insult to the patient. Therefore, in the cases where acetabular reconstruction was deemed necessary, a large diameter head (36 mm) was used, or a dual mobility acetabular prosthesis was inserted in an attempt to reduce post operative instability.
Proximal femoral endoprosthetic reconstruction was performed using the Modular Endoprosthetic Tumour System (Stanmore Implants Wordlwide, Elstree, London, UK). The system comprises modularity to the trochanter, body and stem, allowing accurate restoration of length and offset. It incorporates a hydroxyapatite collar and has been demonstrated to reduce aseptic loosening at the cement-bone interface (17) . The stem of the prosthesis comprises a curved cobalt-chromium component, which was cemented in all cases, using Palacos cement (Zimmer-Biomet Warsaw, Inianna, USA). The femoral canal was prepared by broaching and a cement restrictor inserted distal to the isthmus to improve cement pressurisation. Cement was cleared form the proximal diaphysis to prevent interposition between the diaphysis and the hydroxyapatite collar. In all cases, a single deep vacuum drain was used to minimise haematoma formation, which was removed when the drainage volume decreased to <100ml/24 hours, typically 2-3 days post operation. Postoperatively, an abduction wedge was used for the first 24 hours and all patients were mobilised full weight-bearing under the guidance of a physiotherapist from the 1 st postoperative day. According to our hospital policy, venous thromboembolism prophylaxis consisted of low molecular weight heparin (enoxaparin) for 28 days from operation which was started after review of the drainage output, typically 24 hours post operation, calf compression pumps until mobile and thromboembolic deterrent stockings for 6 weeks.
Continuous data were analysed with descriptive statistics and a Students' t-test. Survival analysis was done with the Kaplan-Meier method. For all other tests, a p value <0.05 was considered significant. All analyses were completed using StatView software (Berkley, California, USA).
Results
There was a significant improvement in the OHS from a mean preoperative score of 8 (range 0-16) to a mean postoperative score of 31 points (range 19-40) at the latest follow-up (p<0.05). 10 patients were able to mobilise without a walking aid and without hip pain, 17 were able to mobilise with the assistance of a single walking aid, 5 with the assistance of 2 walking aids, and 5 described difficulty with all mobilisation.
9 (24%) patients had died at the time of final follow-up. The mean time to death was 33 months (range 3-62 months). 1 patient died within 90 days of operation. The cause of death was a lower respiratory tract infection. The patient suffered with severe obstructive pulmonary airways disease. The patient had made an uneventful recovery from their proximal femoral EPR and had been discharged home following surgery. The 90-day mortality following proximal femoral EPR, therefore, was 2.7%.
When considering revision for any cause as the end-point, the 1-and 5-year (for those attaining 5-year follow-up) survival was 97.3 % and 94.6% respectively. When considering the femoral prosthesis, 1 component required revision for infection with a consequent survival of the femoral component of 97.3% at 1 and 5 years. This population, however, has inherent variation in patient status and bone physiology, and long-term implant survival data is not likely to be reliably reproducible.
The immediate postoperative radiographs demonstrated a congruent hip in all cases. No femoral prostheses demonstrated progressive lucent lines or a lucent line at the cement bone interface >1 mm. In 19 hips, with a minimum follow-up of 12 months, bony ingrowth from the femoral diaphysis onto the hydroxyapatite collar was seen.
Major complications occurred in 3 patients (8%), of who 2 required revision of prosthesis (5.4%). These comprised a periprosthetic infection, which occurred after 12 months of the index procedure. In 1 patient, debridement, antibiotics and retention of prosthesis with exchange of modular components successfully treated the infection to latest follow up. In the second patient, the infection was not controlled by multiple debridement procedures, retaining the prosthesis. Therefore, a 2-stage revision was performed with insertion of an antibiotic-laden interval cement spacer and administration of intravenous antibiotics. Reimplantation with a further proximal femoral EPR following eradication of the infection was undertaken and at latest follow-up, now 4 years post second stage revision, the patient remained free of infection. 1 patient dislocated their prosthesis 7 days post implantation, which required revision of the acetabular component to a constrained acetabular prosthesis. Minor complications occurred in 1 patient (2.7%) who developed cellulitis 10 days post operation. This caused a delay in discharge but was successfully treated with intravenous antibiotics, and no patients required surgery following their index EPR.
All patients had satisfactory restoration of leg lengths, to within 2 cm of the contralateral limb, assessed clinically and radiologically post operation. No patients required a shoe raise or orthosis to compensate for a postoperative leg length discrepancy.
Discussion
Whilst there have been significant advances in the management of proximal femoral bone defects, the challenge of the elderly, comorbid patient requiring revision arthroplasty of the proximal femur remains a clinical dilemma. Accompanying these advances has been a similar advance in the use of modular endoprostheses, initially in the oncology setting, but increasingly being applied to salvage arthroplasty. The use of such devices in the salvage scenario is certainly not new. Sim and Chao (18) in 1981 reported outcomes of 21 patients treated with a proximal femoral replacement for a non-oncological diagnosis. Most recently, Lundh et al (19) reported on a case series of 5 patients. In all the series reported thus far, a principle complication following proximal femoral replacement remains dislocation. In our series, 1 (2.7%) patient suffered postoperative dislocation. This compares favourably to all other series with >20 patients (1, 4, 8, 18, (20) (21) (22) . The incidence of postoperative instability is greater than seen following revision arthroplasty (23, 24) . The reason for this is multifactorial but most likely relates to the poor quality soft tissue envelope encountered following multiple revision procedures. It should be noted, however, that in our series, instability was seen in an 88-year-old undergoing proximal femoral replacement for a comminuted proximal femoral fracture, without previous arthroplasty. The lack of secure fixation of soft tissues to the prosthesis, coupled with the extensive dissection required, will also predispose to instability (25, 26) . Whilst the average age in our cohort was 80 years, the youngest was 49 years. Due to the higher functional status of younger patients', dislocation risk is greater and we included all ages meeting the indication of deficient proximal femoral bone stock. This allowed analysis on an intention to treat basis, and we found no correlation of outcome (particularly stability) with age. The relatively low incidence of instability in our series may be reflected by the preservation of the abductor mechanism through the use of a trochanteric slide. The low incidence of instability in this series may also, in part, be explained by the use of modular prostheses, which more accurately restore limb length and soft tissue tension, and reduces the risk of large limb length discrepancy. If limb length discrepancy does still remain this can be managed with orthotic modification of foot wear.
Whilst we recognise that this study has relatively short follow-up, longer term follow-up to assess dislocation risk is less valuable due to the typical nature of early presentation of instability. The only case of instability in this series occurred at 7 days following implant insertion, and was corrected with acetabular revision. Parvizi et al (1) reported no incidence of instability at a mean of 36.5 months following proximal femoral replacement for non-oncological diagnoses, which they explained in part by their use of a modular prosthesis.
In a recent systematic review of the use of proximal femoral endoprosthetic replacements for non-oncological diagnoses, Korim et al (10) compared the available evidence from 14 studies with a total of 356 patients. At a variable follow-up, complications were recorded in 102 and included dislocation (average 16%) and infection (average 8%). It should be noted, all be it at a relatively short duration of follow-up, that we did not encounter any evidence of aseptic loosening or implant fracture. In the study of Malkani et al (20) , comprising 50 proximal femoral endoprosthetic replacements at a mean follow-up of 11 years, 4 femoral components and 7 acetabular components required revision for aseptic loosening. However, this complication was not seen for Al-Taki et al (4) who reported on the outcomes of 63 patients and demonstrated no aseptic loosening. In our series, all prostheses included an HA collar at the bone prosthesis interface. This has largely eradicated aseptic loosening as a cause of failure for distal femoral endoprostheses in the oncology population (17) , and is likely to demonstrate equally positive results for the proximal femur in the nononcological population.
Revision arthroplasty surgeons, reluctant to undertake proximal femoral replacement in the elderly comorbid population, often point to presumed higher rates of wound complication, infection and subsequent reoperation. In fact, pooled data from the available evidence does not support this with wound healing and soft tissue complications occurring in 0.8% respectively, and infection rates of 8% (10) . Mortality rates range from 0% to 40% with a duration of follow-up between 1.5 and 5 years (1, 4, 8, 11, (18) (19) (20) (21) (22) (27) (28) (29) (30) . In this study, the early postoperative mortality rate was 2.7% at a minimum of 3 months. This, albeit relative, low mortality rate is despite a high incidence of comorbidities within the study population. No patients recorded an ASA score better than 2 and the majority were ASA 3 at the time of operation. The mean Charlson comorbidity index was 4, also reflecting the infirmity of the study population. This compares favourably with the perioperative mortality demonstrated in octogenarians undergoing revision hip arthroplasty (31) . In their study, Parvizi et al (31) demonstrated a 90-day mortality of 2.84% in a population with a mean age of 83.8 years and a mean ASA of 2.7. The low perioperative mortality reported in this study is most likely multi-factorial. All procedures were performed by a surgeon specialising in oncology and revision arthroplasty, used to managing significant bone loss and endoprostheses. This is demonstrated by the relatively short duration of surgery, which averaged 128 minutes (range 69-213 minutes), which compares to the mean operative time of 3 hours (1.5-4.2) reported by Parvizi et al (31) . All patients were managed in a high dependency unit in the postoperative period. These factors, coupled with careful patient selection, will no doubt result in improvements in postoperative mortality, although attributing causation to particular factors, such as early weight bearing is not likely to be easily concluded given the rarity and heterogeneity of managing femoral bone loss with EPR. We suggest that it may be management of patient factors that contribute more significantly to mortality than the surgical insult of EPR use, as opposed to other revision options in this population, although establishing statistical evidence from our results is not possible due to inherent patient variation. If so, patient selection is crucial and distal fixation prosthesis that preserve bone should always be considered in the 1 st instance where possible. Implant cost for the majority of modern revision implants is significant and EPR is no exception. The cost of implants used in this cohort is £3-4000 depending upon length and bearing materials. The overall cost of managing patients with high comorbidity and bone loss is dramatically higher. We suggest that early mobilisation reduces the burden of cardiorespiratory disease and significantly reduces inpatient length of stay, justifying the implant cost -which is small compared to the overall financial burden.
This study has a number of limitations. Firstly, it is a retrospective analysis with an inherent risk of variability in data collection. However, this was countered by the careful scrutiny of patient records to ensure a complete data series. Secondly, this is a single surgeon series. The use of such devices by those not experienced in endoprosthetic replacement surgery, or the ability to select patients suitable for the prosthesis, will likely result in an increase in complications and perioperative mortality.
We have reported a low incidence of perioperative complications in this high-risk population, following proximal femoral endoprosthetic replacement for a breadth of nononcological indications. Our mortality rate is in keeping with other non-EPR multiple revision series, and whilst instability and infection remain the principle complications following EPR, the technique is safe in the appropriately selected elderly and comorbid patient, presenting with significant proximal femoral bone deficiency.
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